Responses
Clinical and epidemiological research
Extended report
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
Compose a Response to This Article
Other responses
No responses have been published for this article.